The study by Potter et al., using genomic single-cell analysis (SCA) in the evaluation of samples obtained from AML patients carrying the NPM1 mutation, has identified a number of branching subclones that had been undetectable in leukemic bulk cells and these specific subclones could be associated with disease relapse [17]. The gene discussed is NPM1; the disease is acute myeloid leukemia.